J. Son

发表

Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.

K. S. Rao, M. Krishnaiah, Y. Sheen, 2011, Bioorganic & medicinal chemistry.

Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.

K. S. Rao, Hyun-Ju Park, M. Krishnaiah, 2011, European journal of medicinal chemistry.

Synthesis and biological evaluation of 1-substituted-3-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.

K. S. Rao, M. Krishnaiah, Y. Sheen, 2011, Bioorganic & medicinal chemistry letters.

EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung.

Y. Sheen, C. Jin, Dae-Kee Kim, 2011, European journal of cancer.

An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition.

Jeong-Seok Nam, So-Yeon Park, Y. Sheen, 2014, Cancer letters.

HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis

E. Lee, Yeong-Wook Song, J. Park, 2016, Arthritis Research & Therapy.

Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).

Keunchil Park, E. Cho, Dong-Wan Kim, 2015 .

THU0499 Hm71224, A Novel Oral BTK Inhibitor, Inhibits Human Immune Cell Activation: New Drug Candidate to Treat B-Cell Associated Autoimmune Diseases

J. K. Park, Y. Lee, J. A. Park, 2014 .

Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs).

Keunchil Park, Dong-Wan Kim, Dae-Ho Lee, 2014 .

Abstract LB-100: Discovery of HM61713 as an orally available and mutant EGFR selective inhibitor

Ji Yeon Song, Jaeho Lee, J. Son, 2014 .

Abstract CT079: ELUXA 1: Ph II study of BI1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)

P. Jänne, S. Ou, Keunchil Park, 2016 .

BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.

Keunchil Park, E. Cho, Dong-Wan Kim, 2016 .

476TiPPhase II study of BI1482694 in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)

P. Jänne, M. Uttenreuther-Fischer, K. Park, 2015 .

190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI).

P. Jänne, S. Ou, Keunchil Park, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.